Edition:
United Kingdom

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.80USD
8:30pm GMT
Change (% chg)

$-0.15 (-2.52%)
Prev Close
$5.95
Open
$6.00
Day's High
$6.15
Day's Low
$5.78
Volume
34,811
Avg. Vol
50,324
52-wk High
$13.75
52-wk Low
$4.90

Chart for

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $320.94
Shares Outstanding(Mil.): 42.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage:

11 Dec 2017

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

06 Nov 2017

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder

05 Sep 2017

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

05 Sep 2017

BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

* Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

25 Aug 2017

BRIEF-Minerva Neurosciences Q2 loss per share $0.27

* Minerva Neurosciences reports second quarter 2017 financial results and business updates

03 Aug 2017

BRIEF-American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results

* American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia

31 Jul 2017

BRIEF-Minerva Neurosciences announces departure of directors

* Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen

24 Jul 2017

BRIEF-Minerva Neurosciences announces departure of directors

* Minerva Neurosciences announces departure of directors Source text for Eikon: Further company coverage:

24 Jul 2017

BRIEF-Minerva Neurosciences prices 5 mln common shares at $7.75 per share

* Minerva neurosciences announces pricing of public offering of common stock

28 Jun 2017

Earnings vs. Estimates